HC Wainwright Issues Pessimistic Forecast for Invivyd (NASDAQ:IVVD) Stock Price

Invivyd (NASDAQ:IVVD) had its price objective decreased by stock analysts at HC Wainwright from $15.00 to $10.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Stock Performance

Invivyd stock opened at $0.70 on Wednesday. The company has a 50-day simple moving average of $0.97 and a 200-day simple moving average of $1.25. The firm has a market capitalization of $83.71 million, a P/E ratio of -0.36 and a beta of 0.65. Invivyd has a one year low of $0.70 and a one year high of $5.20.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently modified their holdings of the stock. Proficio Capital Partners LLC bought a new position in Invivyd in the third quarter worth $27,000. XTX Topco Ltd lifted its position in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. SG Americas Securities LLC lifted its position in Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after purchasing an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. bought a new position in Invivyd in the second quarter worth $86,000. Finally, Rhumbline Advisers lifted its position in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.